Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Johns Hopkins...

    Johns Hopkins University, Bristol-Myers must face 1 Billion Dollar syphilis infections suit

    Farhat NasimWritten by Farhat Nasim Published On 2019-01-05T09:30:20+05:30  |  Updated On 5 Jan 2019 9:30 AM IST
    Johns Hopkins University, Bristol-Myers must face 1 Billion Dollar syphilis infections suit

    U.S: A federal judge in Maryland said The Johns Hopkins University, Bristol-Myers Squibb Co and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis.


    In a decision on Thursday, U.S. District Judge Theodore Chuang rejected the defendants’ argument that a recent Supreme Court decision shielding foreign corporations from lawsuits in U.S. courts over human rights abuses abroad also applied to domestic corporations absent Congressional authorization.


    Chuang’s decision is a victory for 444 victims and relatives of victims suing over the experiment, which was aimed at testing the then-new drug penicillin and stopping the spread of sexually-transmitted diseases.


    The experiment echoed the government’s Tuskegee study on black American men who were deliberately left untreated for syphilis even after penicillin was discovered.


    It was kept under wraps until a professor at Wellesley College in Massachusetts discovered it in 2010. U.S. officials apologized for the experiment, and President Barack Obama called Guatemala’s president to offer a personal apology.


    Chuang said lawsuits against U.S. corporations under the federal Alien Tort Statute were not “categorically foreclosed” by the Supreme Court decision last April 24 in Jesner v Arab Bank Plc covering foreign corporations.


    He said the “need for judicial caution” was “markedly reduced” where U.S. corporations were defendants because there was no threat of diplomatic tensions or objections from foreign governments.


    The judge also said letting the Guatemala case proceed would “promote harmony” by giving foreign plaintiffs a chance at a remedy in U.S. courts.


    According to the complaint, several Hopkins and Rockefeller Foundation doctors were involved with the experiment, as were four executives from Bristol-Myers predecessors, Bristol Laboratories and the Squibb Institute.


    “Johns Hopkins expresses profound sympathy for individuals and families impacted by the deplorable 1940s syphilis study funded and conducted by the U.S. government in Guatemala,” the university said in a statement. “We respect the legal process, and we will continue to vigorously defend the lawsuit.”


    A Rockefeller Foundation spokesman said that the lawsuit had no merit and that the nonprofit did not know about, design, fund or manage the experiment. Bristol-Myers spokesman Brian Castelli declined to comment.


    Paul Bekman, a lawyer for the plaintiffs, said his clients will proceed with discovery, including the exchange of decades-old documents. An earlier ruling found no statute of limitations issues if the plaintiffs could not have learned about the experiment before 2010.



    Also Read: Bristol-Myers Squibb buying Celgene in Rs 7400 crores deal
    Brian CastelliBristol LaboratoriesBristol-Myers Squibb CoGuatemala caseGuatemalansjohn hopkinspenicillinRockefeller FoundationsyphilisThe Johns Hopkins UniversityTheodore ChuangUS
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok